Sonoma Pharmaceuticals, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended March 31, 2019, compared with FY2018. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide separate Q4 results.
Business context
Sonoma is a specialty pharmaceutical company selling dermatology, eye-care, tissue-care and animal-health products, primarily based on stabilized hypochlorous acid (HOCl). It also operates a microbiology testing laboratory and sells through direct sales and distributors in the U.S. and internationally.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Total revenue | $18.970 million | $16.658 million |
| Gross profit / gross margin | $8.880 million / 47% | $7.310 million / 44% |
| Operating expenses | $20.138 million | $21.499 million |
| Operating loss | $11.258 million | $14.189 million |
| Net loss | $11.798 million | $14.328 million |
| Operating cash used | $11.717 million | $12.439 million |
| Cash and cash equivalents at year-end | $3.689 million | $10.066 million |
| Working capital at year-end | $8.905 million | $12.993 million |
Revenue increased 14%, led by product sales, which rose 14% to $17.881 million; service revenue increased 9% to $1.089 million. U.S. product revenue grew 8% to $9.040 million, Latin America grew 32% to $3.962 million, and Europe and the rest of the world grew 14% to $4.879 million. U.S. dermatology sales were flat. Animal-health product sales increased to $1.969 million from $1.386 million.
Product gross margin improved to 48% from 45%; service gross margin was 31% versus 32%. SG&A declined 7% to $18.620 million, reflecting cost reductions, partly offset by $881,000 of severance costs. R&D expense was $1.518 million, down 4%. Interest expense was $33,000; the filing does not present a conventional operating margin as a headline metric.
Net cash used in investing was $131,000; financing provided $5.492 million, primarily from equity and preferred-stock offerings. Long-term debt was $334,000, including $322,000 current; capital-lease obligations were $141,000, all current. Contractual obligations totaled $1.171 million. Accounts receivable, net rose to $3.481 million from $1.537 million.
Material changes and notable items
- Revenue and gross profit improved, while net loss narrowed 18% year over year. Cash declined by $6.377 million during FY2019.
- Leadership changed in December 2018: the former CEO and CFO resigned, and Frederick “Bubba” Sandford became CEO and interim CFO. The company reduced headcount and reported severance expense.
- Epicyn, a prescription topical cleanser, was launched. Management reported early benefits from cost measures and production-efficiency efforts, and expected further progress in FY2020; no quantified financial guidance was provided.
- On May 20, 2019, after year-end, Sonoma sold certain Asian and European animal-health rights and assets for $2.7 million and agreed to supply Petagon for five years. The proceeds are not included in FY2019 cash.
- A 1-for-9 reverse stock split took effect June 19, 2019. The company also reported a Nasdaq minimum-bid-price deficiency and said Nasdaq had not yet made a final determination as of June 27, 2019.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern explanatory paragraph. The filing states that recurring losses and the need for additional funding raise substantial doubt about the company’s ability to continue as a going concern.
Outlook, risks and contingencies
Management expects continued losses and says additional capital may be needed to sustain operations, develop products and commercialize them. It cannot assure that financing will be available on acceptable terms. The auditor’s going-concern statement underscores this funding risk. If capital is unavailable, the company may cut costs or curtail development, sales and marketing, and international activities.
Management expects Latin American revenue to decline substantially as Invekra establishes its own manufacturing; Sonoma’s transition supply arrangement may continue until no later than October 2020. Invekra-related product revenue was $3.376 million in FY2019, approximately 18% of total revenue. The company also cited rebate pressure, seasonal demand related to insurance deductibles, limited reimbursement, customer concentration, foreign-exchange exposure, regulatory and manufacturing risks, competition, and reliance on key personnel and distributors.
The filing identifies potential severance payments of $454,000 to key executives if triggered. It also records a $270,000 liability related to an October 2018 unregistered share sale, which could expose the company to rescission claims, damages or penalties. Management described ordinary-course legal matters as currently insignificant but noted that litigation could have a material adverse effect.
Most important facts for investors to verify
- Cash runway, near-term funding needs, and whether subsequent financing or the $2.7 million asset-sale proceeds provide adequate liquidity.
- Nasdaq’s final determination on bid-price compliance following the reverse split, and the current share count and potential dilution from warrants, options and preferred securities.
- Whether U.S. dermatology growth can offset expected reductions in Invekra-related and other international revenue, and how the Petagon supply agreement affects margins.
- Collection and quality of receivables, which increased materially, and the durability of revenue growth and gross-margin improvement.
- Resolution of the unregistered-share liability and any material developments in legal, regulatory, reimbursement or manufacturing matters.